Fatma Soliman Elsayed Ebeid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fatma Soliman Elsayed Ebeid has a total of 283 co-authors. Here are the top co-authors by number of shared publications:
- Manal Hamdy El-Sayed
Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt
8 shared publications - Mohsen Saleh Elalfy
Pediatric Hematology/Oncology Children's Hospital, Ain Shams University, Faculty of Medicine, Cairo, Egypt
6 shared publications - Azza Abdel Gawad Tantawy
Pediatrics Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
5 shared publications Mohsen Saleh ElAlfy
Ain Shams University
5 shared publicationsAmira A. M. Adly
Pediatric Hematology Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
4 shared publications- Baba Inusa
Faculty of Life Sciences and Medicine, King’s College London, London, United Kingdom
4 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Springer Nature in The European Journal of Health Economics
- p. 1-15
Psychometric properties of EQ-5D-Y-3L versus EQ-5D-Y-5L Arabic versions in healthy and diseased children
- 30 September 2026
- Published by Springer Nature in The European Journal of Health Economics
- p. 1-15
Open AccessPsychometric properties of EQ-5D-Y-3L versus EQ-5D-Y-5L Arabic versions in healthy and diseased children
- Open Access
- 24 September 2026
- Published by Elsevier in Pediatric Hematology Oncology Journal
- Vol. 11 (4)
Clinical characteristics of vincristine-induced neurotoxicity in children with acute lymphoblastic leukemia
- 24 September 2026
- Published by Elsevier in Pediatric Hematology Oncology Journal
- Vol. 11 (4)
Open AccessClinical characteristics of vincristine-induced neurotoxicity in children with acute lymphoblastic leukemia
- 30 March 2026
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- p. 1-17
Central auditory processing in children with sickle cell disease
The complexity of sickle cell disease (SCD) goes beyond hematological manifestations, affecting different organs and systems, including auditory system. We aimed to assess Central Auditory Processing (CAP) abilities in children with SCD as well as to detect risk factors for Auditory Processing Disorders (APD) in children with SCD. A diagnostic observational cross sectional study that included thirty-three patients aged 6-16 years with a confirmed diagnosis of SCD. Demographic, clinical and laboratory characteristics were collected. Audiological testing included tympanometry, pure tone audiometry, IQ testing, specific history for CAP abilities and APD screening test battery. Among the 33 screened patients, all had normal pure tone audiometry, and 2 patients had middle ear affection. Auditory Perception was assessed in 25 eligible participants. The majority of the studied patients (n = 21, 84%) APD. The most affected tests were patterning (n = 21, 84%) and auditory memory (n = 16, 64%). Results showed positive correlation between age of transfusion and dichotic listening, APD was commonly encountered in children with SCD, thus screening for APD is recommended in all patients with SCD for early detection and intervention of any abnormalities.
- 30 March 2026
- Published by Taylor & Francis in Pediatric Hematology and Oncology
- p. 1-17
Central auditory processing in children with sickle cell disease
The complexity of sickle cell disease (SCD) goes beyond hematological manifestations, affecting different organs and systems, including auditory system. We aimed to assess Central Auditory Processing (CAP) abilities in children with SCD as well as to detect risk factors for Auditory Processing Disorders (APD) in children with SCD. A diagnostic observational cross sectional study that included thirty-three patients aged 6-16 years with a confirmed diagnosis of SCD. Demographic, clinical and laboratory characteristics were collected. Audiological testing included tympanometry, pure tone audiometry, IQ testing, specific history for CAP abilities and APD screening test battery. Among the 33 screened patients, all had normal pure tone audiometry, and 2 patients had middle ear affection. Auditory Perception was assessed in 25 eligible participants. The majority of the studied patients (n = 21, 84%) APD. The most affected tests were patterning (n = 21, 84%) and auditory memory (n = 16, 64%). Results showed positive correlation between age of transfusion and dichotic listening, APD was commonly encountered in children with SCD, thus screening for APD is recommended in all patients with SCD for early detection and intervention of any abnormalities.
- Open Access
- 12 February 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1)
Translation and cultural adaptation of the EQ-5D-Y-5L into Modern Standard Arabic for use in Egypt
Background: The use of the EQ-5D-Y-5L to evaluate children and adolescents’ health-related quality of life (HRQOL) is an essential contribution to economic evaluation methods. Accurate translation and cultural adaptation of questionnaires are crucial for their effective use, enabling comparison of data across different languages. Therefore, this study aimed to translate and culturally adapt the EQ-5D-Y-5L into Standard Arabic for use in Egypt. Methodology: The translation process was done according to the methodology and translation guidelines approved by the EuroQol Group Version Management Committee. Two forward translations into Arabic, then two back translations to English were performed, independently. The third step was conducting cognitive interviews with the children, which included a card-ranking exercise, self-completion of the translated Arabic questionnaire, and detailed discussion with the children about the questionnaire sentences. The last step was proofreading of the final Arabic version of the questionnaire. Results: The first Arabic versions of the paper and digital questionnaires were created after the forward translation. Following the back translation, only one modification was made in the digital source of the Arabic version. Cognitive interviews were conducted with 11 children with a mean age of 10.6 years. Some changes were suggested based on the initial 8 interviews in the Pain or Discomfort dimension and in the visual analogue scale (VAS) instructions. Three additional interviews were carried out to discuss these changes, and all were accepted. The final Arabic version was then developed after proofreading. Conclusions: The Standard Arabic version of the EQ-5D-Y-5L produced in this study is an acceptable version that can be used in Egypt and other Arabic-speaking countries.
- 12 February 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1)
Open AccessTranslation and cultural adaptation of the EQ-5D-Y-5L into Modern Standard Arabic for use in Egypt
Background: The use of the EQ-5D-Y-5L to evaluate children and adolescents’ health-related quality of life (HRQOL) is an essential contribution to economic evaluation methods. Accurate translation and cultural adaptation of questionnaires are crucial for their effective use, enabling comparison of data across different languages. Therefore, this study aimed to translate and culturally adapt the EQ-5D-Y-5L into Standard Arabic for use in Egypt. Methodology: The translation process was done according to the methodology and translation guidelines approved by the EuroQol Group Version Management Committee. Two forward translations into Arabic, then two back translations to English were performed, independently. The third step was conducting cognitive interviews with the children, which included a card-ranking exercise, self-completion of the translated Arabic questionnaire, and detailed discussion with the children about the questionnaire sentences. The last step was proofreading of the final Arabic version of the questionnaire. Results: The first Arabic versions of the paper and digital questionnaires were created after the forward translation. Following the back translation, only one modification was made in the digital source of the Arabic version. Cognitive interviews were conducted with 11 children with a mean age of 10.6 years. Some changes were suggested based on the initial 8 interviews in the Pain or Discomfort dimension and in the visual analogue scale (VAS) instructions. Three additional interviews were carried out to discuss these changes, and all were accepted. The final Arabic version was then developed after proofreading. Conclusions: The Standard Arabic version of the EQ-5D-Y-5L produced in this study is an acceptable version that can be used in Egypt and other Arabic-speaking countries.
- Open Access
- 22 December 2025
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 26 (1)
UNC13D mutations in Egyptian children with hemophagocytic lymphohistiocytosis
Background: Familial hemophagocytic lymphohistiocytosis (FHL) is invariably fatal without appropriate treatment. This study evaluated the frequency and types of UNC13D mutations in patients fulfilling HLH criteria and correlated them with disease severity. Forty suspected HLH patients underwent detailed medical history and clinical examination. Complete blood count, liver enzymes, total and direct bilirubin, serum ferritin, serum fibrinogen, serum triglycerides, soluble CD25, bone marrow aspirate, brain MRI, CSF analysis, and genetic testing were performed. Results: Forty patients were recruited with mean age of 34 months at diagnosis. Twenty-five (62.5%) patients had mutations for FHL, 10 of them had UNC13D mutations which represented the second most common gene mutation in our cohort. Missense mutation c.902 A>G was the most prevalent ( n = 4, 40%) detected mutation in UNC13D group. There was no significant difference between patients with UNC13D mutations and other patients as regards clinical, laboratory, radiological findings or outcome except that all patients with UNC13D mutations admitted to ICU were due to disease rather than sepsis ( p < 0.001). Conclusion: UNC13D mutations is the second most common FHL among Egyptian children with clinical features comparable to other subtypes, highlighting the need for larger multicenter studies to better define genotype-phenotype correlations.
- 22 December 2025
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 26 (1)
Open AccessUNC13D mutations in Egyptian children with hemophagocytic lymphohistiocytosis
Background: Familial hemophagocytic lymphohistiocytosis (FHL) is invariably fatal without appropriate treatment. This study evaluated the frequency and types of UNC13D mutations in patients fulfilling HLH criteria and correlated them with disease severity. Forty suspected HLH patients underwent detailed medical history and clinical examination. Complete blood count, liver enzymes, total and direct bilirubin, serum ferritin, serum fibrinogen, serum triglycerides, soluble CD25, bone marrow aspirate, brain MRI, CSF analysis, and genetic testing were performed. Results: Forty patients were recruited with mean age of 34 months at diagnosis. Twenty-five (62.5%) patients had mutations for FHL, 10 of them had UNC13D mutations which represented the second most common gene mutation in our cohort. Missense mutation c.902 A>G was the most prevalent ( n = 4, 40%) detected mutation in UNC13D group. There was no significant difference between patients with UNC13D mutations and other patients as regards clinical, laboratory, radiological findings or outcome except that all patients with UNC13D mutations admitted to ICU were due to disease rather than sepsis ( p < 0.001). Conclusion: UNC13D mutations is the second most common FHL among Egyptian children with clinical features comparable to other subtypes, highlighting the need for larger multicenter studies to better define genotype-phenotype correlations.
- 6 September 2025
- Published by Wiley in Liver International
- Vol. 45 (10) , e70329
Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in Young Children With Chronic HCV Infection
Background and Aims: Sofosbuvir (SOF) plus daclatasvir (DCV) is a primary chronic hepatitis C virus (HCV) treatment in low‐ and middle‐income countries. WHO guidelines recommend a half‐adult dose for children (14–25 kg) based on pharmacokinetic modelling, requiring clinical validation. We evaluated the pharmacokinetics, safety, efficacy and acceptability of DCV (30 mg) and SOF (200 mg) in children weighing 14 to < 17 kg and 17–35 kg. Methods: Children (3–13 years; 14–35 kg) with chronic HCV received a daily paediatric formulation of DCV 30 mg and SOF 200 mg for 12 weeks. Intensive steady‐state PK sampling was performed. Efficacy was assessed by sustained virologic response at 12 weeks post‐treatment (SVR12), and adverse events were monitored. Results: Twenty‐three patients were enrolled in two groups: 14 to < 17 kg ( n = 11; median age 5 [3–8] years) and 17–35 kg ( n = 12; median age 7 [5–13] years). For children 14 to < 17 kg, mean (CV%) AUC24 (ng·h/mL) and C maxss (ng/mL) were 14 875 (55) and 1604 (48) for DCV; 2683 (65) and 1562 (69) for SOF; and 10 456 (77) and 1420 (84) for GS‐331007. For children 17–35 kg, values were 11 082 (47) and 1062 (32) for DCV; 2125 (88) and 952 (61) for SOF; and 15 256 (27) and 1606 (46) for GS‐331007. All patients achieved SVR12, with good acceptability and no serious adverse events. Conclusions: For children 14–35 kg with chronic HCV, half the adult dose of DCV (30 mg) and SOF (200 mg) offered comparable exposure, safety, efficacy and acceptability to the adult regimen. Trial Registration: ClinicalTrials.gov identifier: NCT0585451
- 6 September 2025
- Published by Wiley in Liver International
- Vol. 45 (10) , e70329
Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in Young Children With Chronic HCV Infection
Background and Aims: Sofosbuvir (SOF) plus daclatasvir (DCV) is a primary chronic hepatitis C virus (HCV) treatment in low‐ and middle‐income countries. WHO guidelines recommend a half‐adult dose for children (14–25 kg) based on pharmacokinetic modelling, requiring clinical validation. We evaluated the pharmacokinetics, safety, efficacy and acceptability of DCV (30 mg) and SOF (200 mg) in children weighing 14 to < 17 kg and 17–35 kg. Methods: Children (3–13 years; 14–35 kg) with chronic HCV received a daily paediatric formulation of DCV 30 mg and SOF 200 mg for 12 weeks. Intensive steady‐state PK sampling was performed. Efficacy was assessed by sustained virologic response at 12 weeks post‐treatment (SVR12), and adverse events were monitored. Results: Twenty‐three patients were enrolled in two groups: 14 to < 17 kg ( n = 11; median age 5 [3–8] years) and 17–35 kg ( n = 12; median age 7 [5–13] years). For children 14 to < 17 kg, mean (CV%) AUC24 (ng·h/mL) and C maxss (ng/mL) were 14 875 (55) and 1604 (48) for DCV; 2683 (65) and 1562 (69) for SOF; and 10 456 (77) and 1420 (84) for GS‐331007. For children 17–35 kg, values were 11 082 (47) and 1062 (32) for DCV; 2125 (88) and 952 (61) for SOF; and 15 256 (27) and 1606 (46) for GS‐331007. All patients achieved SVR12, with good acceptability and no serious adverse events. Conclusions: For children 14–35 kg with chronic HCV, half the adult dose of DCV (30 mg) and SOF (200 mg) offered comparable exposure, safety, efficacy and acceptability to the adult regimen. Trial Registration: ClinicalTrials.gov identifier: NCT0585451
- 18 April 2025
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 18 (6) , 481-490
Vasculopathy among children and adolescents with sickle cell disease: the crosstalk with annexin A1, vitamin D, and myocardial iron overload
Annexin A1 plays an important role in myocardial defense against ischemia-reperfusion injury. We aimed to evaluate the role of annexin A1 as a potential marker of vasculopathy in children and adolescents with sickle cell disease (SCD) and its relation to myocardial iron content (MIC) and vitamin D status. Forty-one patients with SCD were compared with 40 age- and sex-matched healthy controls, and underwent assessment of serum annexin A1, vitamin D, Doppler echocardiography and cardiac magnetic resonance (CMR). Six (14.6%) SCD patients had cardiac disease, five (12.2%) had abnormal MIC (≥1.16) and 10 (24.4%) had pulmonary hypertension risk. Annexin A1 levels were significantly lower among patients with SCD compared with healthy controls (p < 0.001). SCD patients with pulmonary hypertension risk, evidence of diastolic dysfunction, and nephropathy as well as those with serum ferritin ≥ 2500 µg/L and vitamin D deficiency had lower Annexin A1 levels than those without. Serum annexin A1 levels were negatively correlated to urinary albumin creatinine ratio (UACR) and Tei index while positively correlated to vitamin D among SCD patients. Annexin A1 could be a promising marker of vasculopathy and may provide a biochemical explanation for vitamin D deficiency in SCD.
- 18 April 2025
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 18 (6) , 481-490
Vasculopathy among children and adolescents with sickle cell disease: the crosstalk with annexin A1, vitamin D, and myocardial iron overload
Annexin A1 plays an important role in myocardial defense against ischemia-reperfusion injury. We aimed to evaluate the role of annexin A1 as a potential marker of vasculopathy in children and adolescents with sickle cell disease (SCD) and its relation to myocardial iron content (MIC) and vitamin D status. Forty-one patients with SCD were compared with 40 age- and sex-matched healthy controls, and underwent assessment of serum annexin A1, vitamin D, Doppler echocardiography and cardiac magnetic resonance (CMR). Six (14.6%) SCD patients had cardiac disease, five (12.2%) had abnormal MIC (≥1.16) and 10 (24.4%) had pulmonary hypertension risk. Annexin A1 levels were significantly lower among patients with SCD compared with healthy controls (p < 0.001). SCD patients with pulmonary hypertension risk, evidence of diastolic dysfunction, and nephropathy as well as those with serum ferritin ≥ 2500 µg/L and vitamin D deficiency had lower Annexin A1 levels than those without. Serum annexin A1 levels were negatively correlated to urinary albumin creatinine ratio (UACR) and Tei index while positively correlated to vitamin D among SCD patients. Annexin A1 could be a promising marker of vasculopathy and may provide a biochemical explanation for vitamin D deficiency in SCD.
- Open Access
- 10 January 2025
- Published by Springer Nature in Egyptian Pediatric Association Gazette
- Vol. 73 (1) , 1-10
Clinical manifestations of COVID-19 infection and its impact on the outcome in children and adolescents with benign and malignant hematological disease in Egypt: a single-center experience
Background: It is known that viral infections are associated with increased morbidity and mortality in immunocompromised children. Few reports describe the clinical manifestations and outcomes of COVID-19 infection in children and adolescents with benign and malignant hematological disease with a large sample size from our Egyptian population. Aim: As a preliminary step in developing a national registry for children and adolescents with hemato-oncological disease who were diagnosed with COVID-19 infection, in this study we aimed to determine (a) the frequency of COVID-19 infection in children with hematological disease, (b) the presenting clinical manifestations, and (c) the associated underlying disease outcome and its clinical determinants. Methods: We collected data from medical records of a retrospective cohort including all children and adolescent patients who were known to have a benign or malignant hematological disease attending the hematology and oncology outpatient clinic or were hospitalized between February 2022 and March 2023 in a university hospital in Cairo, Egypt, for tertiary care. All patients (n = 620) were tested for SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) test by nasopharyngeal swab. For all patients, the collected data included the demographic data, diagnosis, cause of hospital visit, cause and duration of admission if needed, presence of symptoms suggestive of COVID-19 infection, and concurrent medications. Baseline laboratory investigation were collected included complete blood count (CBC), liver and kidney functions, C-reactive protein (CRP), serum ferritin, lactate dehydrogenase, and coagulation test. For COVID-19-positive patients, the additional data collected included the duration of COVID-19 infection, its course, full examination during this illness, its severity, and the outcome of COVID-19 infection and the underlying disease. Results: Out of the 620 children and adolescents with benign (n = 271) and malignant (n = 349) hematological diseases in in-patients and out-patients’ settings, 86 patients (13.8%) tested positive for SARS-CoV-2. COVID-19 infection was more common in patients with hematological malignancy (n = 56, 65.1%) than those with benign hematological disease (27 patients, 31.4%). Among COVID-19-positive patients, 20 patients (23.3%) required intensive care unit admission compared to 30 (5.6%) COVID-19-negative patients (p-value < 0.000). Death was reported in 5 COVID-19-positive patients (5.8%) compared to 19 in COVID-19-negative patients (3.6%) (p-value = 0.314). The factors associated with mortality in COVID-19-positive patients (3 patients with hematological malignancy and 2 patients with aplastic anemia) was abnormal neurological examination [OR = 17.3; p-value = 0.009]. Conclusion: The current study showed that COVID-19 was higher among patients with hematological malignancies than those with benign hematological disease. COVID-19 was tolerable among the studied patients with underlying hematological disease where 94.1% of the COVID-19-positive patients survived. Mortality was associated with abnormal neurological examination in COVID-19-positive patients with underlying hematological disease.
- 10 January 2025
- Published by Springer Nature in Egyptian Pediatric Association Gazette
- Vol. 73 (1) , 1-10
Open AccessClinical manifestations of COVID-19 infection and its impact on the outcome in children and adolescents with benign and malignant hematological disease in Egypt: a single-center experience
Background: It is known that viral infections are associated with increased morbidity and mortality in immunocompromised children. Few reports describe the clinical manifestations and outcomes of COVID-19 infection in children and adolescents with benign and malignant hematological disease with a large sample size from our Egyptian population. Aim: As a preliminary step in developing a national registry for children and adolescents with hemato-oncological disease who were diagnosed with COVID-19 infection, in this study we aimed to determine (a) the frequency of COVID-19 infection in children with hematological disease, (b) the presenting clinical manifestations, and (c) the associated underlying disease outcome and its clinical determinants. Methods: We collected data from medical records of a retrospective cohort including all children and adolescent patients who were known to have a benign or malignant hematological disease attending the hematology and oncology outpatient clinic or were hospitalized between February 2022 and March 2023 in a university hospital in Cairo, Egypt, for tertiary care. All patients (n = 620) were tested for SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) test by nasopharyngeal swab. For all patients, the collected data included the demographic data, diagnosis, cause of hospital visit, cause and duration of admission if needed, presence of symptoms suggestive of COVID-19 infection, and concurrent medications. Baseline laboratory investigation were collected included complete blood count (CBC), liver and kidney functions, C-reactive protein (CRP), serum ferritin, lactate dehydrogenase, and coagulation test. For COVID-19-positive patients, the additional data collected included the duration of COVID-19 infection, its course, full examination during this illness, its severity, and the outcome of COVID-19 infection and the underlying disease. Results: Out of the 620 children and adolescents with benign (n = 271) and malignant (n = 349) hematological diseases in in-patients and out-patients’ settings, 86 patients (13.8%) tested positive for SARS-CoV-2. COVID-19 infection was more common in patients with hematological malignancy (n = 56, 65.1%) than those with benign hematological disease (27 patients, 31.4%). Among COVID-19-positive patients, 20 patients (23.3%) required intensive care unit admission compared to 30 (5.6%) COVID-19-negative patients (p-value < 0.000). Death was reported in 5 COVID-19-positive patients (5.8%) compared to 19 in COVID-19-negative patients (3.6%) (p-value = 0.314). The factors associated with mortality in COVID-19-positive patients (3 patients with hematological malignancy and 2 patients with aplastic anemia) was abnormal neurological examination [OR = 17.3; p-value = 0.009]. Conclusion: The current study showed that COVID-19 was higher among patients with hematological malignancies than those with benign hematological disease. COVID-19 was tolerable among the studied patients with underlying hematological disease where 94.1% of the COVID-19-positive patients survived. Mortality was associated with abnormal neurological examination in COVID-19-positive patients with underlying hematological disease.
- 19 December 2024
- Published by Elsevier in Clinical Therapeutics
- Vol. 47 (2) , e5-e15
Population Pharmacokinetics of Ledipasvir/Sofosbuvir in Pediatric Patients: Impact of Acute Lymphoblastic Leukemia
- 19 December 2024
- Published by Elsevier in Clinical Therapeutics
- Vol. 47 (2) , e5-e15
Population Pharmacokinetics of Ledipasvir/Sofosbuvir in Pediatric Patients: Impact of Acute Lymphoblastic Leukemia
- 27 November 2024
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 17 (12) , 967-975
The impact of oral health promotion on the quality of life of children with bleeding disorders: fighting misconceptions
Background: Understanding the disease-specific risks and patient-related barriers of children with bleeding disorders is necessary for primary oral health promotion. Our goal was to assess the oral health status and the impact of oral health promotion among patients with bleeding disorders. Research design and methods: At baseline, 70 patients with inherited and acquired bleeding disorders had a complete intraoral examination, completed the oral health-related quality of life (OHRQoL) questionnaires, and an oral health education was given. After 6 months, the effectiveness of the oral hygiene promotion was evaluated clinically and through the OHRQoL questionnaires. Results: Our cohort included 33 patients with chronic immune thrombocytopenia (cITP), 27 hemophilia A patients, and 10 with inherited thrombasthenia. Forty patients (57.1%) had dental caries, 90.0% showed fair oral hygiene status with variable degrees of gingivitis. The baseline self-image score was significantly inferior among patients with inherited bleeding disorders, while the psychological domain for family was greatly affected among cITP patients. After 6 months, there was a significant reduction in the oral debris, the modified gingival indexes, the percentages of cases with oral bleeding, and a significantly improved mean OHRQoL total score. Conclusions: After the oral health education, the OHRQoL scores had significantly improved, and oral hygiene status were acceptable among patients with bleeding disorders.
- 27 November 2024
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 17 (12) , 967-975
The impact of oral health promotion on the quality of life of children with bleeding disorders: fighting misconceptions
Background: Understanding the disease-specific risks and patient-related barriers of children with bleeding disorders is necessary for primary oral health promotion. Our goal was to assess the oral health status and the impact of oral health promotion among patients with bleeding disorders. Research design and methods: At baseline, 70 patients with inherited and acquired bleeding disorders had a complete intraoral examination, completed the oral health-related quality of life (OHRQoL) questionnaires, and an oral health education was given. After 6 months, the effectiveness of the oral hygiene promotion was evaluated clinically and through the OHRQoL questionnaires. Results: Our cohort included 33 patients with chronic immune thrombocytopenia (cITP), 27 hemophilia A patients, and 10 with inherited thrombasthenia. Forty patients (57.1%) had dental caries, 90.0% showed fair oral hygiene status with variable degrees of gingivitis. The baseline self-image score was significantly inferior among patients with inherited bleeding disorders, while the psychological domain for family was greatly affected among cITP patients. After 6 months, there was a significant reduction in the oral debris, the modified gingival indexes, the percentages of cases with oral bleeding, and a significantly improved mean OHRQoL total score. Conclusions: After the oral health education, the OHRQoL scores had significantly improved, and oral hygiene status were acceptable among patients with bleeding disorders.